Catalytic inhibition of DNA topoisomerase IIα by sodium azide

被引:12
|
作者
Ju, R [1 ]
Mao, YH [1 ]
Glick, MJ [1 ]
Muller, MT [1 ]
Snyder, RD [1 ]
机构
[1] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA
关键词
azide; ICT assay; topoisomerase II alpha;
D O I
10.1016/S0378-4274(01)00328-9
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
It has been demonstrated previously that sodium azide reduces the clastogenicity of several DNA topoisomerase II (topo II) poisons in cultured mammalian cells. These studies suggested that azide may be a catalytic topo II inhibitor. Azide interferes with mitochondrial production of ATP and is also known to inhibit cellular ATPases. Since topo II requires ATP for catalytic activity (enzyme turnover), it seemed likely that interference with ATP levels or ATP catabolism was the underlying mechanism of topo II inactivation; however, this has not been examined in living cells under conditions where the endogenous topo II is active on genomic DNA. The present studies were carried out to verify that azide inhibits endogenous topo II in cells. We show that azide blocks both decatenation and relaxation activity of purified topo II in a concentration dependent manner and reduces topoII/DNA covalent complex formation in cells. From these studies, it is concluded that sodium azide catalytically inactivates topo II via an ATP-sensitive process. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 50 条
  • [21] Human DNA topoisomerase II-α expression in laparoscopically treated renal cell carcinoma
    Dekel, Y
    Frede, T
    Kugel, V
    Neumann, G
    Rassweiler, J
    Koren, R
    ONCOLOGY REPORTS, 2005, 14 (01) : 271 - 274
  • [22] DNA Topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms
    Joseph A. Holden
    Endocrine Pathology, 1999, 10 : 97 - 102
  • [23] DNA topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms
    Holden, JA
    ENDOCRINE PATHOLOGY, 1999, 10 (02) : 97 - 102
  • [24] The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues
    Turley, H
    Comley, M
    Houlbrook, S
    Nozaki, N
    Kikuchi, A
    Hickson, ID
    Gatter, K
    Harris, AL
    BRITISH JOURNAL OF CANCER, 1997, 75 (09) : 1340 - 1346
  • [25] Structural characterization of sodium azide and sodium bifluoride at high pressures
    Millar, David I. A.
    Barry, Christopher
    Marshall, William G.
    Pulham, Colin R.
    ZEITSCHRIFT FUR KRISTALLOGRAPHIE-CRYSTALLINE MATERIALS, 2014, 229 (03): : 259 - 275
  • [26] SPECTROPHOTOMETRIC REACTION-RATE METHOD FOR THE DETERMINATION OF SULFIDE BY CATALYTIC ACTION ON THE OXIDATION OF SODIUM-AZIDE BY IODINE
    ENSAFI, AA
    SAMIMIFAR, M
    ANALYTICAL LETTERS, 1994, 27 (01) : 153 - 167
  • [27] Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II interacting agents
    Perrin, D
    van Hille, B
    Hill, BT
    BIOCHEMICAL PHARMACOLOGY, 1998, 56 (04) : 503 - 507
  • [28] Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIα and β -: Distinct mode of action of two derivatives
    Krishna, ADS
    Panda, G
    Kondapi, AK
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2005, 438 (02) : 206 - 216
  • [29] Molecular Dynamics Simulation Study on the Effect of Oxali-Palladium as a Catalytic Inhibitor of Human Topoisomerase IIα
    Tavakoli, Nadia
    Ghalandari, Behafarid
    Badalkhani-Khamseh, Farideh
    Ding, Xianting
    Divsalar, Adeleh
    IRANIAN JOURNAL OF SCIENCE AND TECHNOLOGY TRANSACTION A-SCIENCE, 2022, 46 (06): : 1575 - 1582
  • [30] DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer
    Nakopoulou, L
    Lazaris, A
    Kavantzas, N
    Alexandrou, P
    Athanassiadou, P
    Keramopoulos, A
    Davaris, P
    PATHOBIOLOGY, 2000, 68 (03) : 137 - 143